skip to Main Content

Pancreatic Cancer Trial Platform Poised to Lead to Quicker, More Efficient Research

Newsfeed image, light gray text on dark gray background
Due to the prevalence, low survival rates, and complexity of the disease, there is an unmet need for novel therapies in pancreatic cancer with a quicker turnaround, according to Vincent J. Picozzi Jr, MD.

However, with the design of the Precision PromiseTM clinical trial platform, conducted by the Pancreatic Cancer Action Network (PanCAN), and a number of participating sites, experts in the field are hopeful that this new approach will be standardized across malignancies. Read more . . . 


Back To Top